Sustained release formulations of metformin

Details Sustained release formulations of metformin Sustained release formulations of metformin

2007-05-08

2007-05-08

Sheikh, Humera N. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S464000, C424S465000, C424S474000, C424S479000, C424S480000, C424S481000, C424S482000, C424S451000, C424S489000, C424S490000

Reexamination Certificate

active

10630239

ABSTRACT:
The invention provides sustained release formulations of metformin or a pharmaceutically acceptable salt thereof, and methods of treating diabetes by administering to a patient a therapeutically effective amount of a sustained release formulation of metformin or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 3629393 (1971-12-01), Nakamoto et al.
patent: 4351825 (1982-09-01), Sothmann et al.
patent: 4828836 (1989-05-01), Elger et al.
patent: 5055306 (1991-10-01), Barry et al.
patent: 5128143 (1992-07-01), Baichwal et al.
patent: 5135757 (1992-08-01), Baichwal et al.
patent: 5330767 (1994-07-01), Yamamoto et al.
patent: 5399358 (1995-03-01), Baichwal et al.
patent: 5399359 (1995-03-01), Baichwal
patent: 5455046 (1995-10-01), Baichwal
patent: 5512297 (1996-04-01), Baichwal
patent: 5554387 (1996-09-01), Baichwal
patent: 5611971 (1997-03-01), Maedera et al.
patent: 5631021 (1997-05-01), Okada et al.
patent: 5651990 (1997-07-01), Takada et al.
patent: 5670168 (1997-09-01), Baichwal et al.
patent: 5955106 (1999-09-01), Moeckel et al.
patent: 6056977 (2000-05-01), Bhagwat et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 44 32 757 (1996-03-01), None
patent: 0 360 562 (1990-03-01), None
patent: 0 251 459 (1992-07-01), None
patent: 0 642 785 (1995-03-01), None
patent: 0 709 085 (1996-05-01), None
patent: 0 749 751 (1996-12-01), None
patent: 0 531 497 (1997-08-01), None
patent: 0 580 428 (1997-10-01), None
patent: 97/17975 (1997-05-01), None
patent: WO-97/16172 (1997-05-01), None
patent: WO-97/39050 (1997-10-01), None
patent: WO-98/01117 (1998-01-01), None
patent: 99/47128 (1999-09-01), None
patent: WO-01/22940 (2001-04-01), None
patent: WO-93/01803 (2003-02-01), None
Campbell, et al., “A Clinical Evaluation of a Delayed Release Preparation of Metformin,”J Int Med Res, vol. 1, pp. 551-556 (1973).
Pentikainen, “Bioavailability of Metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products,”Int J Clin Pharmacol, Ther and Toxicol, vol. 4, pp. 213-220 (1986).
Abdallah, et al., “Preparation and evaluation of metformin hydrochloride controlled-release tablets,”S.T.P. Pharma, vol. 4(1), pp. 15-20 (1988).
Karttunen, et al., “The Pharmacokinetics of metformin: a comparison of the properties of a rapid-release and sustained-release preparation,”Int J Clin Pharmacol, Ther and Toxicol, vol. 21(1), pp. 31-36 (1983).
Mosby's GenRx, “Drug Names—Metformin Hydrochloride (3204) Categories, Brand Names, Formularies & Cost of Therapy,” (1998) pp. 1-17.
Saleh, “Tablets produced under licence Do they have the same dissolution characteristics and drug content uniformity as the original ones? Example: metformin hydrochloride sustained-release tablets,”S.T.P. Pharma, vol. 6(8), pp. 598-603 (1990).
Grdinic, et al., “Comparison of in-vitro release and renal elimination of 1-butylbiguanide from times-release oral antidiabetic preparations,”Acta Pharm. Jugoslav., vol. 29, pp. 215-221 (1979).
Dimitrijevic, et al., “Electro-Responsive Release From A Chondroitin Sulphate Hydrogel,”J. Pharm. Pharmacology., vol. 47, pp. 1058 (1995).
Karttunen, “The Influence of Pharmaceutical Formulation on the Gastrointestinal Side Effects of Metformin,”Scandinavian Society for the Study of Diabetes, 15thAnnual Meeting, Norway (1980).
Noel, “Kinetic Study of Normal and Sustained Release Dosage Forms of Metformin in Normal Subjects,”Research and Clinical Forums, vol. 1(4), pp. 35-50 (1979).
Noel, “Kinetic Study of Normal and Sustained Release Dosage Forms of Metformin in Normal Subjects,”Journal of International Biomedical Information and Data, vol. 1(1), pp. 9-20 (1980).
Bristol-Myers Squibb, “Glucophage XR (Metformin HC1 extended-release) Tablets, Rx,”FDA Website, (Posted Oct. 20, 2000).
“Glucophage Retard,” The Role Liste (1993).
Araman, et a,, “In Vivo-In Vitro Correlation of Prolinged Release Metformin HCL Tablets Prepared with Coating Materials,”Supplement F, Supplement to Pharmaceutisch Weekblad Scientific Edition, 1stEuropean Congress of Pharmaceutical Science, vol. 14(5) (1992).
Stanforth, “Synergistically Interacting Heterodisperse Polysaccharides—Function in Achieving Controllable Drug Delivery,” American Chemical Society (1993).
Dhopeshwarkar et al., Evaluation of Xanthan Gum in the Preparation of Sustained Release Matrix Tablets, Drug Development and Industrial Pharmacy, 19(9), 999-1017 (1993).
Supplemental European Search Report dated Jul. 4, 2006.

Affiliated with

Also associated with

Rating

Sustained release formulations of metformin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release formulations of metformin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release formulations of metformin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3724327